Anavex Life Sciences (AVXL) vs Neumora Therapeutics (NMRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Anavex Life Sciences (AVXL) has outperformed Neumora Therapeutics (NMRA) over the past year, losing 81.9% versus a loss of 85.7%. Neumora Therapeutics is the larger company by market cap ($63.0 million vs $54.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVXL | NMRA |
|---|---|---|
| Share price | $0.5915 | $0.3339 |
| Market cap | $54.83M | $63.01M |
| 1-day change | -11.39% | -3.78% |
| YTD return | -83.38% | -81.35% |
| 1-year return | -81.86% | -85.67% |
| 5-year return | -96.96% | — |
| EPS (TTM) | $-0.14 | $-1.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-46.38M | $-236.93M |
| 52-week high | $5.36 | $3.65 |
| 52-week low | $0.59 | $0.301 |
| Distance from 52-week high | -88.96% | -90.85% |
| Analyst consensus | none | buy |
| Avg. price target upside | — | +1696.95% |
| Average volume | 1.15M | 1.69M |
| Shares outstanding | 92.70M | 188.69M |
| Employees | 34 | 63 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Anavex Life Sciences
AVXL stock →Anavex Life Sciences Corp. operates as a biopharmaceutical company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 34 employees
About Neumora Therapeutics
NMRA stock →Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 63 employees
AVXL vs NMRA FAQ
Which is bigger, Anavex Life Sciences or Neumora Therapeutics?
Neumora Therapeutics (NMRA) is larger, with a market capitalization of $63.01M compared with $54.83M for Anavex Life Sciences (AVXL).
Which stock has performed better over the past year, AVXL or NMRA?
AVXL returned -81.86% over the past 12 months, compared with -85.67% for NMRA (price return, excluding dividends). Past performance does not predict future results.
Are Anavex Life Sciences and Neumora Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.